RELATED SERVICES
Dr. Zhibin Li focuses his practices on complex intellectual property issues, with an emphasis on pharmaceutical Hatch-Waxman litigation. Zhibin has been involved in various aspects of such litigations, including:
- Paragraph IV Certifications
- Non-infringement and invalidity contentions
- Fact discovery
- Preliminary injunction
- Claim construction
- Expert discovery
- Motion practice
- Pre-trial
- Trial
Additionally, Zhibin has experience in patent preparation and prosecution.
Dr. Zhibin Li focuses his practices on complex intellectual property issues, with an emphasis on pharmaceutical Hatch-Waxman litigation. Zhibin has been involved in various aspects of such litigations, including:
- Paragraph IV Certifications
- Non-infringement and invalidity contentions
- Fact discovery
- Preliminary injunction
- Claim construction
- Expert discovery
- Motion practice
- Pre-trial
- Trial
Additionally, Zhibin has experience in patent preparation and prosecution.
Zhibin's experience spans a wide range of technical areas within the life sciences, including pharmaceuticals, chemistry, nanomaterials, polymers, biotechnology and medical devices.
Prior to joining the Firm, Zhibin was a Principal Scientist at a major pharmaceutical company with research experience in solid form (polymorphs, salts and cocrystals) screening and API crystallization. In addition to his pharmaceutical experience and chemistry training, Zhibin also has extensive experience in material characterization using scattering (neutron, X-ray, light), microscopic (TEM, SEM, AFM, and optical) and thermo (DSC, TGA) methods in understanding materials with sizes ranging from nano- to micro-scale.
Zhibin is a co-inventor of four patents and an author/co-author of more than 30 scientific publications.
Zhibin's experience includes:
- Representing generic drug manufacturer in Paragraph IV Hatch-Waxman patent infringement litigation concerning:
- An oral formulation used to treat heart failure (Entresto®)
- An oral formulation used to treat schizophrenia (Rexulti®)
- An oral formulation used to treat breast cancer (Ibrance®)
- An oral formulation used to treat Type II diabetes (Farxiga®)
- Topical solutions used to treat onychomycosis (Jublia®)
- Oral formulations used to treat hypertriglyceridemia (Vascepa®)
- Oral formulations of opioids used to treat pain (Opana® ER)
- Represented clients from different industries, including pharmaceutical, chemical, semiconductor, materials and mechanical, in preparation and prosecution of patent applications
CREDENTIALS
- J.D., University of Connecticut School of Law, 2014
- M.B.A., University of Connecticut School of Business, 2014
- Ph.D., Chemistry, University of Tennessee, 2002
- B.S., Applied Chemistry, University of Science and Technology of China, 1996
- New York
- New Jersey
- U.S. Patent and Trademark Office
- U.S. Court of Appeals for the Federal Circuit
- U.S. District Court for the District of New Jersey
- Mandarin Chinese
- Named, Top ANDA Litigator, Patexia ANDA Litigation Intelligence Report (2021-2023)
- Named, Ones to Watch, The Best Lawyers in America®, Intellectual Property Law (2024)
- Partner, Locke Lord LLP
- Associate, Locke Lord LLP (2015-2023)
- Principal Scientist at a major pharmaceutical company, Ridgefield, CT (2006-2015)
- Post-doctoral Research Fellow, Department of Material Science and Engineering, University of Delaware, Newark, DE (2004-2006)
- Post-doctoral Research Fellow, Department of Chemistry, Rensselaer Polytechnic Institute, Troy, NY (2002-2003)